09.07.16
Dr. Ole Isacson has been appointed chief scientific officer of Pfizer’s Neuroscience Research Unit and senior vice president, effective September 16. Dr. Isacson is a world-renowned scientist and Professor of Neurology at Harvard Medical School. He is also a founding director of the Neuroregeneration Institute at McLean Hospital. Dr. Isacson will report to Mikael Dolsten, president of Worldwide R&D.
Dr. Isacson held a two-year postdoctoral fellowship at Cambridge University in England before joining Harvard in 1989. During the past 20 years, Dr. Isacson’s lab has become known as one of the most recognized academic research centers for Parkinson’s disease and other neurodegenerative disorders.
“Dr. Isacson’s deep expertise in neurodegenerative disorders is well-aligned with our work in Alzheimer’s and Parkinson’s disease, where we are working to advance potential breakthrough therapies to fill the tremendous unmet need that exists for patients,” said Dr. Dolsten. “In addition, his strong ties in the local academic community will be important as our Cambridge site continues to drive collaborations with leading scientific and academic institutions that can help us speed the pace of discovery.”
Dr. Isacson held a two-year postdoctoral fellowship at Cambridge University in England before joining Harvard in 1989. During the past 20 years, Dr. Isacson’s lab has become known as one of the most recognized academic research centers for Parkinson’s disease and other neurodegenerative disorders.
“Dr. Isacson’s deep expertise in neurodegenerative disorders is well-aligned with our work in Alzheimer’s and Parkinson’s disease, where we are working to advance potential breakthrough therapies to fill the tremendous unmet need that exists for patients,” said Dr. Dolsten. “In addition, his strong ties in the local academic community will be important as our Cambridge site continues to drive collaborations with leading scientific and academic institutions that can help us speed the pace of discovery.”